Thursday, AstraZeneca reported data from the Phase III ADAURA trial showing its Tagrisso (osimertinib) boosts overall survival (OS) as an adjuvant treatment for early non-small cell lung cancer (NSCLC) after curative resection.

Lilly

Eli Lilly isn’t having a good year in Alzheimer’s disease. Data released Wednesday from the Phase III A4 study showed solanezumab fell short of its primary endpoint, failing to slow cognitive decline in patients with preclinical Alzheimer’s disease. 

brain scan

ALS is the 5,000-piece jigsaw puzzle of the therapeutic world. As the regulatory edges come together, new research pieces are also connecting. 

Akebia Therapeutics announced another delay Tuesday in a series of setbacks for vadadustat, being developed to treat anemia linked to chronic kidney disease (CKD). 

Actinium Pharmaceuticals’ Iomab-B met the primary endpoint in the Phase III SIERRA trial, demonstrating durable Complete Remission (dCR) at six months in patients with relapsed or refractory acute myeloid leukemia (r/r AML).

Bristol Myers Squibb and 2seventy bio published positive results Friday from a pivotal trial of their B-cell maturation antigen–directed (BCMA) CAR T-cell therapy in multiple myeloma patients who had received two to four prior lines of therapy.

Roche

Data from the Phase III COMMODORE 2 study show Roche-subsidiary Genentech’s investigational antibody crovalimab is non-inferior to AstraZeneca’s Soliris (eculizumab), the current standard of care in paroxysmal nocturnal hemoglobinuria (PNH).

Sanofi

Sanofi is discontinuing its Phase III study of tolebrutinib, an investigational BTK inhibitor for myasthenia gravis (MG), the company announced Friday in its full-year 2022 financial report.

uniQure inked a deal with Apic Bio Tuesday to gain development and commercialization rights for APB-102, a therapeutic intended to treat a rare, genetic form of ALS. 

Moderna

The FDA granted Moderna’s RSV vaccine candidate Breakthrough Therapy Designation Monday.